VITRAKVI 20 mg / ml Oral solution

Licence status
Authorised: 19/09/2019
Active substances
LAROTRECTINIB SULFATE
Dosage Form
Oral solution
Licence number
EU/1/19/1385/003-004
Licence holder
Bayer AG

Product documents

Licence information

ATC code
L01XE53 Larotrecetinib sulfate, larotrecetinib
Legal supply status
Product subject to prescription which may not be renewed (A)
Place of sale
Supply through pharmacies only
Conditions of Licence
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing availability
Unknown
Advertising conditions
Advertising to healthcare professionals only
Licence issued
19/09/2019